We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Aurinia Pharmaceuticals Inc (AUPH) NPV

Sell:$5.02 Buy:$5.03 Change: $0.01 (0.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$5.02
Buy:$5.03
Change: $0.01 (0.20%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$5.02
Buy:$5.03
Change: $0.01 (0.20%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Contact details

Address:
#140, 14315 - 118 AVENUE
VICTORIA
T5L 4S6
Canada
Telephone:
+1 (250) 7442487
Website:
https://www.auriniapharma.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AUPH
ISIN:
CA05156V1022
Market cap:
$737.55 million
Shares in issue:
144.62 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Canada
Currency:
US dollar
Indices:
n/a

Key personnel

  • Daniel Billen
    Chairman of the Board
  • Peter Greenleaf
    President, Chief Executive Officer, Director
  • Joe Miller
    Chief Financial Officer
  • Stephen Robertson
    Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Matthew Donley
    Executive Vice President, Operations and Strategy
  • Scott Habig
    Chief Commercial Officer
  • Greg Keenan
    Chief Medical Officer
  • Michael Martin
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.